PNC-27 10mg

PNC-27 is a chimeric peptide that combines a segment of the p53 tumor suppressor protein with a membrane-penetrating (membranolytic) leader sequence. The peptide was designed to selectively destroy cancer cells by exploiting a unique feature of their membrane biology: many cancer cells overexpress HDM-2 (human double minute 2, also called MDM2) on their cell surface, while normal cells keep HDM-2 intracellular. The p53-derived segment of PNC-27 contains the HDM-2 binding domain of p53 (residues 12-26). When PNC-27 encounters cancer cells with surface-exposed HDM-2, it binds HDM-2 and, through its membranolytic leader sequence, disrupts the cell membrane, causing rapid necrotic cell death. In normal cells, where HDM-2 is not expressed on the surface, PNC-27 cannot bind and therefore has no membranolytic effect. Research by Kanovsky et al. demonstrated that PNC-27 kills multiple cancer cell lines (breast, leukemia, melanoma, pancreatic) while leaving normal cells unharmed. The selectivity depends entirely on surface HDM-2 expression, which has been confirmed in multiple cancer types. This represents a unique anticancer mechanism — neither classical apoptosis induction nor immune-mediated killing, but rather physical destruction of the cancer cell membrane through targeted binding.

PNC-27 is a chimeric peptide that combines a segment of the p53 tumor suppressor protein with a membrane-penetrating (membranolytic) leader sequence. The peptide was designed to selectively destroy cancer cells by exploiting a unique feature of their membrane biology: many cancer cells overexpress HDM-2 (human double minute 2, also called MDM2) on their cell surface, while normal cells keep HDM-2 intracellular. The p53-derived segment of PNC-27 contains the HDM-2 binding domain of p53 (residues 12-26). When PNC-27 encounters cancer cells with surface-exposed HDM-2, it binds HDM-2 and, through its membranolytic leader sequence, disrupts the cell membrane, causing rapid necrotic cell death. In normal cells, where HDM-2 is not expressed on the surface, PNC-27 cannot bind and therefore has no membranolytic effect. Research by Kanovsky et al. demonstrated that PNC-27 kills multiple cancer cell lines (breast, leukemia, melanoma, pancreatic) while leaving normal cells unharmed. The selectivity depends entirely on surface HDM-2 expression, which has been confirmed in multiple cancer types. This represents a unique anticancer mechanism — neither classical apoptosis induction nor immune-mediated killing, but rather physical destruction of the cancer cell membrane through targeted binding.

In vitro cancer cell studies use 50-200 micromolar. Xenograft studies in mice use IP injections at doses designed to achieve local tumor concentrations in this range.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.